Patrick Legembre

List of Publications by Year
in descending order

84 papers	5,681 citations	159585 30 h-index	76900 74 g-index
94 all docs	94 docs citations	94 times ranked	12224 citing authors

#	Article	IF	Citations
1	Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii. Microbes and Infection, 2022, , 104952.	1.9	0
2	Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	5
3	Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors. Cells, 2022, 11, 1438.	4.1	6
4	Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. Biomolecules, 2022, 12, 901.	4.0	2
5	Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Science Translational Medicine, 2021, 13, eabi4994.	12.4	22
6	Single bilateral ovarian venous return in uterine transplant: Validation in an orthotopic auto-transplant model in the Yucatan minipig. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102059.	1.3	3
7	Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188596.	7.4	7
8	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. IScience, 2021, 24, 103348.	4.1	10
9	CD95/Fas suppresses NF-Î²B activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism. IScience, 2021, 24, 103538.	4.1	16
10	CD95/Fas and metastatic disease: What does not kill you makes you stronger. Seminars in Cancer Biology, 2020, 60, 121-131.	9.6	31
11	Editorial: Death Receptors, Non-apoptotic Signaling Pathways and Inflammation. Frontiers in Immunology, 2020, 11, 2162.	4.8	2
12	CD95 Structure, Aggregation and Cell Signaling. Frontiers in Cell and Developmental Biology, 2020, 8, 314.	3.7	28
13	The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis. , 2020, , 171-188.		1
14	Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCÎ³1 interaction analysis. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2094-2099.	2.2	1
15	Probing the side chain tolerance for inhibitors of the CD95/PLCÎ³1 interaction. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126669.	2.2	1
16	HIV protease inhibitors and autoimmunity: An odd, but promising idea. Autoimmunity Reviews, 2019, 18, 102370.	5.8	0
17	Investigation of Phospholipase CÎ³1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4721.	4.1	5
18	An insight into the role of the death receptor CD95 throughout pregnancy: Guardian, facilitator, or foe. Birth Defects Research, 2019, 111, 197-211.	1.5	5

#	Article	IF	Citations
19	Staphylococcus aureus induces DNA damage in host cell. Scientific Reports, 2019, 9, 7694.	3.3	26
20	Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer. Molecular Cancer Research, 2019, 17, 2537-2548.	3.4	10
21	Nonapoptotic functions of Fas/<scp>CD</scp>95 in the immune response. FEBS Journal, 2018, 285, 809-827.	4.7	56
22	Disrupting the CD95â€“PLCÎ³1 interaction prevents Th17-driven inflammation. Nature Chemical Biology, 2018, 14, 1079-1089.	8.0	23
23	Tumor analysis: freezeâ€“thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells. BMC Research Notes, 2018, 11, 401.	1.4	8
24	Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nature Communications, 2018, 9, 3267.	12.8	192
25	Ovarian Cancer Immunity. , 2018, , .		0
26	Chemical Composition, Antioxidant, and Anticancer Effect ofRuta chalepensisâ€™s Extracts against Human Leukemic Cells. Phytotherapie, 2018, 16, S225-S236.	0.1	9
27	CD95 Stimulation with CD95L and DISC Analysis. Methods in Molecular Biology, 2017, 1557, 11-18.	0.9	1
28	Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K. Methods in Molecular Biology, 2017, 1557, 103-110.	0.9	3
29	Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L. Methods in Molecular Biology, 2017, 1557, 117-123.	0.9	2
30	Proximity Ligation Assay (PLA) to Evaluate DISC and MISC Composition. Methods in Molecular Biology, 2017, 1557, 41-48.	0.9	1
31	T cell landscape in triple negative breast cancer patients. Breast, 2017, 32, S99.	2.2	0
32	CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases. Frontiers in Immunology, 2017, 8, 1216.	4.8	64
33	FAS (Fas cell surface death receptor). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017, , .	0.1	0
34	TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. Oncotarget, 2017, 8, 9974-9985.	1.8	68
35	Atypical Immune Functions of CD95/CD95L. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 131-157.	0.1	0
36	Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 283-296.	1.6	35

#	Article	IF	Citations
37	The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca2+ flux from the endoplasmic reticulum to mitochondria. Cell Death and Differentiation, 2016, 23, 1702-1716.	11.2	35
38	The cleaved FAS ligand activates the Na+/H+ exchanger NHE1 through Akt/ROCK1 to stimulate cell motility. Scientific Reports, 2016, 6, 28008.	3.3	17
39	CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. Immunity, 2016, 45, 209-223.	14.3	73
40	Cyaneodimycin, a Bioactive Compound Isolated from the Culture of Streptomyces cyaneofuscatus Associated with Lichina confinis. European Journal of Organic Chemistry, 2016, 2016, 3977-3982.	2.4	17
41	Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?. Annals of Translational Medicine, 2016, 4, 554-554.	1.7	1
42	Sphingolipids modulate the epithelialâ€“mesenchymal transition in cancer. Cell Death Discovery, 2015, 1, 15001.	4.7	16
43	Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. Oncogene, 2015, 34, 996-1005.	5.9	77
44	A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells. Journal of Medicinal Chemistry, 2015, 58, 6559-6573.	6.4	33
45	Chemotherapy with ceramide in TNBC. Oncoscience, 2015, 2, 817-818.	2.2	1
46	The CD95/CD95L signaling pathway: A role in carcinogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 130-141.	7.4	42
47	CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer. Cancer Research, 2013, 73, 6711-6721.	0.9	91
48	Staphylococcus aureus-Induced G2/M Phase Transition Delay in Host Epithelial Cells Increases Bacterial Infective Efficiency. PLoS ONE, 2013, 8, e63279.	2.5	33
49	Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity. PLoS ONE, 2013, 8, e54000.	2.5	15
50	The CD95 signaling pathway. Communicative and Integrative Biology, 2012, 5, 190-192.	1.4	9
51	Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest. Leukemia Research and Treatment, 2012, 2012, 1-9.	2.0	9
52	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
53	Precise Mapping of the CD95 Pre-Ligand Assembly Domain. PLoS ONE, 2012, 7, e46236.	2.5	16
54	CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cellular and Molecular Life Sciences, 2012, 69, 1261-1277.	5.4	47

#	Article	IF	Citations
55	S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligandâ€“Mediated Apoptosis in Cancer Cells. Gastroenterology, 2011, 140, 2009-2018.e4.	1.3	83
56	Does calcium contribute to the CD95 signaling pathway?. Anti-Cancer Drugs, 2011, 22, 481-487.	1.4	9
57	Editorial [Hot topic: Stresses, Death Receptors and Plasma Membrane (Guest Editors: Patrick Legembre) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	0
58	Actinâ€independent exclusion of CD95 by PI3K/AKT signalling: Implications for apoptosis. European Journal of Immunology, 2011, 41, 2368-2378.	2.9	25
59	CD95 triggers Orai1-mediated localized Ca²⁺entry, regulates recruitment of protein kinase C (PKC) Î²2, and prevents death-inducing signaling complex formation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19072-19077.	7.1	52
60	The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway. PLoS Biology, 2011, 9, e1001090.	5.6	92
61	Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 22-28.	1.6	14
62	R9: Potentialisation de la rÃ©ponse apoptotique au Rituximab (RTX) dans les lymphomes B non hodgkinien : rÃ1e du calcium. Bulletin Du Cancer, 2010, 97, S20.	1.6	0
63	Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. European Journal of Cancer, 2010, 46, 1445-1455.	2.8	45
64	The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells. PLoS ONE, 2009, 4, e5493.	2.5	22
65	An atypical necrotic signal induced by immunosuppressive and anti-viral agents. Autophagy, 2009, 5, 425-427.	9.1	3
66	CD95 engagement mediates actin-independent and -dependent apoptotic signals. Cell Death and Differentiation, 2009, 16, 1654-1664.	11.2	26
67	Rewinding the DISC. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 9-14.	2.3	25
68	The Immunosuppressor Mycophenolic Acid Kills Activated Lymphocytes by Inducing a Nonclassical Actin-Dependent Necrotic Signal. Journal of Immunology, 2008, 181, 7630-7638.	0.8	34
69	Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway. Molecular Cancer Research, 2008, 6, 604-613.	3.4	45
70	Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP. Cancer Research, 2007, 67, 108-115.	0.9	17
71	The HA tag is cleaved and loses immunoreactivity during apoptosis. Nature Methods, 2007, 4, 107-108.	19.0	36
72	Cutting Edge: Modulation of Fas-Mediated Apoptosis by Lipid Rafts in T Lymphocytes. Journal of Immunology, 2006, 176, 716-720.	0.8	63

#	Article	IF	Citations
73	Does CD95 have tumor promoting activities?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1755, 25-36.	7.4	56
74	Amplification of Fas-Mediated Apoptosis in Type II Cells via Microdomain Recruitment. Molecular and Cellular Biology, 2005, 25, 6811-6820.	2.3	39
75	Identification of SNF1/AMP Kinase-related Kinase as an NF-Î²B-regulated Anti-apoptotic Kinase Involved in CD95-induced Motility and Invasiveness. Journal of Biological Chemistry, 2004, 279, 46742-46747.	3.4	61
76	The relevance of NF-?B for CD95 Signaling in Tumor Cells. Cell Cycle, 2004, 3, 1235-1239.	2.6	36
77	CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO Journal, 2004, 23, 3175-3185.	7.8	291
78	Induction of apoptosis and activation of NFâ€ÎºB by CD95 require different signalling thresholds. EMBO Reports, 2004, 5, 1084-1089.	4.5	97
79	Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism. British Journal of Haematology, 2003, 120, 782-786.	2.5	40
80	Two CD95 tumor classes with different sensitivities to antitumor drugs. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11445-11450.	7.1	100
81	Cutting Edge: SDS-Stable Fas Microaggregates: An Early Event of Fas Activation Occurring with Agonistic Anti-Fas Antibody but Not with Fas Ligand. Journal of Immunology, 2003, 171, 5659-5662.	0.8	30
82	Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. Cell Death and Differentiation, 2002, 9, 329-339.	11.2	28
83	Identification of Agonistic and Antagonistic Antibodies against gp190, the Leukemia Inhibitory Factor Receptor, Reveals Distinct Roles for Its Two Cytokine-binding Domains. Journal of Biological Chemistry, 2001, 276, 47975-47981.	3.4	7
84	Composition chimique, activitÃ© antioxydante et anticancÃ©reuse des extraits de Ruta chalepensis sur des lignÃ©es de cellules leucÃ©miques humaines. Phytotherapie, 0, , 1.	0.1	1